AstraZeneca PLC (AZN)

NYQ – Real vaqt narxi. Valyuta: USD

184.54

+2.68 (1.47%)

Yopilishda: May 12, 2026, 4:00 PM EDT

184.60

+0.07 (0.04%)

Bozor oldidan: May 13, 2026, 7:03 AM EDT

13.05.2026

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their three-year licensing of K Pro – Owkin's AI Scientist for biopharma decision making. K Pro brings multimodal data and specialized biological agentic AI to each step of the value chain. Under the three-year licensing agreement, Owkin will lead the.

$BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026$

12.05.2026

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it has been selected for a poster presentation of the BI-1206 triplet combination in relapsed/refractory non-Hodgkin's lymphoma (NHL) at the 31st European Hematology Association (EHA2026) Congress, taking place June 11-14, 2026 in Stockholm, Sweden. Poster Presentation Title: Targeting resistance to rituximab through FcγRIIB (CD32B) blockade: BI-1206 + rituximab + acalabrutinib shows powerful activity in R/R NHL Presenter: Dr. Laura Fogliatto, Hospital de Clínicas de Porto Alegre, Brazil Session Date/Time: Friday, June 12, 6:45 pm-7:45 pm CEST (12:45 pm-1:45 pm EDT) Location: EHA2026 Congress, Stockholm The presentation will summarize emerging efficacy and safety observations and mechanistic insights from the ongoing Phase 1/2 study (NCT03571568) evaluating BI-1206 in combination with rituximab and Calquence® (acalabrutinib) in patients with relapsed or refractory NHL, including follicular lymphoma.

10.05.2026

Polen International Growth Q1 2026 Portfolio Activity

In Q1 2026, Polen International Growth Portfolio returned -14.4% (net of fees) compared to -0.7% for the Index. We initiated new positions in TSMC, Rheinmetall, Saab, Mitsubishi Heavy Industries, AstraZeneca, AIA Group, Siemens Energy, Samsung Electronics, and Keyence. We sold our holdings in Nintendo, MakeMyTrip, Adidas, Globant, Amadeus IT Group, Monday.com, ICON plc, and HDFC Bank.

06.05.2026

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.

04.05.2026

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

AbbVie ABBV stock has risen around 5% since it announced robust first-quarter 2026 results on April 29. It beat estimates for both earnings and sales and the guidance for 2026 revenues and earnings was also raised.

02.05.2026

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong guidance—that could serve as a sorely needed tailwind for the healthcare sector.

01.05.2026

AstraZeneca stock falls after FDA panel votes against new cancer drug

An advisory panel for the U.S. Food and Drug Administration voted 6-3 against AstraZeneca's oral drug camizestrant intended for a type of breast cancer tumor, citing concerns around trial design. AstraZeneca's London-listed shares fell on the back of the vote outcome.

Videolar

19.12.2025

Neutral

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

01.12.2025

Neutral

BREAKING: Trump strikes major deal with UK on drug pricing

22.11.2025

Positive

AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer

14.11.2025

Positive

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

Press-relizlar

13.05.2026

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

29.04.2026

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

Option exercise triggers $25M payment to Pinetree. CAMBRIDGE, Mass.

27.04.2026

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's SAPHNELO® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen, for the treatment of adult patients with systemic lupus erythematosus (SLE) on top of standard therapy. The approval by the US Food and Drug Administration (FDA) was based on results from the Phase III TULIP-SC trial, which showed that subcutaneous (SC) administration of SAPHNELO led to a statistically significant and.

20.04.2026

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the annualized rate of moderate-to-severe COPD exacerbations in the primary population of former smokers and in the overall population, which included former and current smokers, and patients across all blood eosinophil* counts and all stages of lung function severity. I.

AstraZeneca PLC (AZN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AstraZeneca PLC (AZN)

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

Polen International Growth Q1 2026 Portfolio Activity

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

AstraZeneca stock falls after FDA panel votes against new cancer drug

Videolar

Press-relizlar

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

Polen International Growth Q1 2026 Portfolio Activity

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

AstraZeneca stock falls after FDA panel votes against new cancer drug

Videolar

Press-relizlar

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

Search stocks

AstraZeneca PLC (AZN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AstraZeneca PLC (AZN)

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

Polen International Growth Q1 2026 Portfolio Activity

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

AstraZeneca stock falls after FDA panel votes against new cancer drug

Videolar

Press-relizlar

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

Polen International Growth Q1 2026 Portfolio Activity

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

AstraZeneca stock falls after FDA panel votes against new cancer drug

Videolar

Press-relizlar

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD